Elsevier

Hearing Research

Volume 356, December 2017, Pages 104-115
Hearing Research

Research Paper
Cannula-based drug delivery to the guinea pig round window causes a lasting hearing loss that may be temporarily mitigated by BDNF

https://doi.org/10.1016/j.heares.2017.10.004Get rights and content

Abstract

Sustained local delivery of drugs to the inner ear may be required for future regenerative and protective strategies. The round window is surgically accessible and a promising delivery route. To be viable, a delivery system should not cause hearing loss. This study determined the effect on hearing of placing a drug-delivery microcatheter on to the round window, and delivering either artificial perilymph (AP) or brain-derived neurotrophic factor (BDNF) via this catheter with a mini-osmotic pump. Auditory brainstem responses (ABRs) were monitored for 4 months after surgery, while the AP or BDNF was administered for the first month. The presence of the microcatheter – whether dry or when delivering AP or BDNF for 4 weeks – was associated with an increase in ABR thresholds of up to 15 dB, 16 weeks after implantation. This threshold shift was, in part, delayed by the delivery of BDNF. We conclude that the chronic presence of a microcatheter in the round window niche causes hearing loss, and that this is exacerbated by delivery of AP, and ameliorated temporarily by delivery of BDNF.

Introduction

The optimal method for local drug administration to the inner ear has not yet been established. Sustained drug delivery via the semi permeable round window membrane (RWM) (Goycoolea and Lundman, 1997) is a promising approach, but not without its challenges. Persistence of the drug to be delivered at the middle ear surface of the RWM is required for sustained delivery (Salt et al., 2011). Varied attempts have been made at increasing this persistence through the use of sustained release biodegradable-solid (Plontke et al., 2014, Silverstein et al., 1999) or viscous carriers (Endo et al., 2005, Salt et al., 2011), such as hydrogels (Piu et al., 2011). Other methods have involved repeated or continuous administration of liquid compounds (Cayé Thomasen et al., 2004, Wagner et al., 2005). One method of achieving continuous administration over a prolonged time course involves the use of a microcatheter placed adjacent to the RWM in its bony niche, connected to a drug delivery pump. This method has seen success in the delivery of glucocorticoids (Lefebvre and Staecker, 2002), aminoglycosides (DeCicco et al., 1998) and neurotrophins (Goycoolea and Lundman, 1997, Sly et al., 2012). This method offers the advantage of a predictable duration of delivery, with a consistent concentration of drug present at the delivery site during that time.

There is a paucity of literature regarding potential adverse local effects of continuous or repeated drug administration to the round window niche. Middle ear granulations have been noted after microcatheter delivery of concentrated glucocorticoids in humans (Plontke et al., 2006, Salt et al., 2011), though the authors suggested that mobility of the catheter due to inadequate fixation was the likely stimulus. Thickening and inflammation of the RWM was noted after repeated intratympanic instillation of hydrocortisone solution (Nordang et al., 2003, Plontke et al., 2014, Silverstein et al., 1999) in rats, though this effect was thought to be due to the specific compound, as instillation of dexamethasone in the same manner resulted in no such changes. Thickening of the RWM has also been seen in response to application of polymyxin E, as well as combination medications (Cortisporin; Monarch Pharmaceuticals, Bristol, USA) containing bacitracin, neomycin, polymyxin B and hydrocortisone, with no thickening in response to triamcinolone or cefmenoxime (Endo et al., 2005, Ikeda et al., 1991, Salt et al., 2011). Experimental stiffening or obliteration of the round window may cause a cochlear conductive hearing loss in guinea pigs (Nageris et al., 2012, Piu et al., 2011), with similar losses seen in human patients with congenital or acquired immobility or obliteration of the RWM (Cayé Thomasen et al., 2004, Linder et al., 2003, Wagner et al., 2005). The primary aim of this paper is to determine whether chronic drug delivery via a microcatheter approach can be performed without risk to hearing. This is important in order to ascertain whether drugs can be applied long-term to the RWM, in order to prevent or treat hearing loss.

One class of proteins with therapeutic potential are the neurotrophins (Lefebvre and Staecker, 2002, Phimister et al., 2015, Sly et al., 2012, Wan et al., 2014). Brain-derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) are of particular interest in inner ear therapeutics, as they have been demonstrated to be critical to the development and neuronal organisation of the cochlea (DeCicco et al., 1998, Staecker et al., 1996a, Staecker et al., 1996c). Both have been shown to aid survival of spiral ganglion neurons in experimental deafness models (Endo et al., 2005, Gillespie et al., 2004, Miller et al., 1997, Noushi et al., 2005, Staecker et al., 1996b), with BDNF also having been shown to improve ABR thresholds beyond baseline at high frequencies in normal-hearing guinea pigs (Sly et al., 2012). More recently there have been suggestions that neurotrophins may have a therapeutic role in the treatment of hidden hearing loss (Phimister et al., 2015, Sly et al., 2016). For these reasons, BDNF was the active drug delivered via the RWM microcatheter in these experiments. Here we examined whether the better-than-normal hearing elicited by neurotrophins (Sly et al., 2012) persisted after cessation of the treatment. This is of interest because although neurotrophins reduce electrically evoked ABR thresholds for the duration of drug delivery some studies have shown that its effect is transient, lasting only as long as the drug is administered (Gillespie et al., 2003, Landry et al., 2011, Shepherd et al., 2005), while others have shown persistent effects long after the neurotrophins delivery has ceased (Ramekers et al., 2015). The reason(s) for these disparate study outcomes are not known, and may be informed by knowing the persistence of neurotrophins' effects on the hearing cochlea.

Section snippets

Materials and methods

Ethics approval for the described experiment was obtained from the Animal Research Ethics Committee of the Royal Victorian Eye and Ear Hospital (project 12/240AR).

Results

Twenty Dunkin Hartley tri-coloured guinea pigs (11 females and 9 males, ranging from 429 to 1037 g) were allocated to AP (n = 6), BDNF (n = 9) or ‘Dry Cannula’ (n = 5) groups.

All drug-delivery manipulations to the round window caused some hearing loss

The presence of the AP had a detrimental effect upon hearing in its own right, being associated with poorer ABR thresholds whilst it was being delivered than afterwards. Whatever the cause for the hearing loss, its transient nature implies a temporary cochlear change. At least two possibilities for this could be considered. The first is that the constant wetting of the RWM changed its physical and mechanical properties. The second is that the ionic content of the AP had a detrimental effect

Conclusions

The presence of a microcatheter adjacent to the RWM was detrimental to hearing, particularly when delivering AP. In this respect, the current paper did not replicate the findings of Sly and colleagues (Sly et al., 2012), where normal saline applied to the round window caused minimal hearing loss. The most likely explanation for the degradation in hearing was either a change in the mechanical properties of the round window, or alternatively a reduction in function of the hair cells. The

Acknowledgements

The authors would like to thank Michelle Stirling (animal husbandry), Scott Chambers and Leon Winata (technical assistance), Prue Nielsen (histological processing) and James Fallon (Igor software routine development) for their assistance. This work was funded by the Garnett Passe and Rodney Williams Memorial Foundation, Melbourne, Australia.

References (46)

  • F.W. Albers et al.

    Ultrastructure of the organ of Corti in experimental hydrops

    Acta Oto-laryngol.

    (1988)
  • P. Cayé Thomasen et al.

    An animal model for continuous drug administration to the inner ear

    Audiol. Med.

    (2004)
  • R.L. Davis

    Gradients of neurotrophins, ion channels, and tuning in the cochlea

    The Neuroscientist

    (2003)
  • M.J. DeCicco et al.

    Round-window microcatheter-administered microdose gentamicin: results from treatment of tinnitus associated with Meniere's disease

    Int. Tinnitus J.

    (1998)
  • E.A. Dunnebier et al.

    Two-phase endolymphatic hydrops: a new dynamic Guinea pig model

    Acta Oto-laryngol.

    (1997)
  • T. Endo et al.

    Novel strategy for treatment of inner ears using a biodegradable gel

    The Laryngoscope

    (2005)
  • L.N. Gillespie et al.

    BDNF-induced survival of auditory neurons in vivo: cessation of treatment leads to accelerated loss of survival effects

    J. Neurosci. Res.

    (2003)
  • L.N. Gillespie et al.

    Delayed neurotrophin treatment supports auditory neuron survival in deaf Guinea pigs

    Neuroreport

    (2004)
  • M.V.M. Goycoolea et al.

    Round window membrane. Structure function and permeability: a review

    Microsc. Res. Tech.

    (1997)
  • D. Huang et al.

    Optical coherence tomography

    Science

    (1991)
  • K. Ikeda et al.

    Otic preparations altered permeability and thickness of the round window membrane of the chinchilla

    J. Oto-Rhino-Laryngol. Head Neck Surg.

    (1991)
  • G.L. Jenison et al.

    Potassium-induced release of endogenous amino acids in the Guinea pig cochlea

    J. Neurochem.

    (1985)
  • X.-H. Jia et al.

    Morphological changes associated with low-tone hearing loss in Guinea pig models of early endolymphatic hydrops

    Sheng Li Xue Bao [Acta Physiol. Sin.]

    (2012)
  • Cited by (8)

    • Inner ear drug delivery: Recent advances, challenges, and perspective

      2019, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      The timeline of degenerative process of auditory neurons was determined in guinea pigs following deafness induced by intratympanic neomycin (Fransson and Ulfendahl, 2017). The placement of a drug-delivery micro-catheter onto RWM of guinea pigs caused a lasting hearing loss that was temporarily mitigated by BDNF (Sale et al., 2017). Despite advances in experimental tools, experimental studies of drug pharmacokinetics in the perilymph still remain technically challenging due to the limited size and inaccessibility of the inner ear without invasive surgery as well as complex drug communication processes in the inner ear.

    • Controlled drug release to the inner ear: Concepts, materials, mechanisms, and performance

      2018, Hearing Research
      Citation Excerpt :

      Therapeutic drug molecules for the inner ear cover a broad range of molecular weights, charges, solubilities, hydrophilicities, lipophilicities, and stress sensitivities (e.g., shear, temperature). Drug molecules include low molecular weight steroids (e.g., dexamethasone) (Borden et al., 2011; El Kechai et al., 2016; Gehrke et al., 2016; Plontke et al., 2014; Salt et al., 2011; Scheper et al., 2017), peptides for endosomal escape (Li et al., 2015b), siRNA (Oishi et al., 2013; Qi et al., 2014), DNA (Wu et al., 2013), proteins (e.g., brain derived neurotropic factor [BDNF]) (Havenith et al., 2011; Sale et al., 2017; Wang et al., 2014), and protein-producing fibroblasts (Hütten et al., 2013). The potency, physicochemical properties, and stability of the drug molecules are key parameters for designing the most suitable DDSs.

    View all citing articles on Scopus
    View full text